FEES FOR THE 2023 FINANCIAL YEAR
| Ernst & Young Audit | Deloitte & Associés | |||||||
|---|---|---|---|---|---|---|---|---|
|
€ millions excl. VAT 2023 |
Auditor Ernst & Young Audit | Network | Total | As a % | Auditor Deloitte & Associés | Network | Total | As a % |
| Review of interim, company and consolidated financial statements | ||||||||
| L’Oréal | 1.7 | n/a | 1.7 | 1.8 | n/a | 1.8 | ||
| Fully consolidated subsidiaries | 0.9 | 4.8 | 5.7 | 0.9 | 5.6 | 6.5 | ||
| Subtotal | 2.6 | 4.8 | 7.4 | 67% | 2.7 | 5.6 | 8.3 | 78% |
| Non-audit services(1) | ||||||||
| L’Oréal | 0.5 | 2.6 | 3.1 | 0.7 | 0.6 | 1.3 | ||
| Fully consolidated subsidiaries | — | 0.5 | 0.5 | — | 1.1 | 1.1 | ||
| Subtotal | 0.5 | 3.1 | 3.6 | 33% | 0.7 | 1.7 | 2.4 | 22% |
| TOTAL |
3.1 |
7.9 |
11.0 |
100% |
3.4 |
7.3 |
10.7 |
100% |
(1) Mainly concerning acquisition audits.
Signing of an agreement for the acquisition of Gowoonsesang Cosmetics Co (Dr. G)
L'Oréal Groupe announced on 23 December 2024 the signing of an agreement with Swiss retail group Migros for the acquisition of its subsidiary Gowoonsesang Cosmetics Co., Ltd., including Dr.G, the Korean skincare brand founded by dermatologist Dr. Gun Young Ahn in 2003 and based in Seoul. Dr.G will join L’Oréal Groupe’s Consumer Products Division (CPD) to address the growing success of K-Beauty worldwide and expand its offering with effective, science-based, yet accessible skincare. The acquisition is subject to customary conditions precedent and is expected to close in the coming months.
Signing of an agreement for the sale of 2.3% of Sanofi shares
L'Oréal Groupe announced on 3 February 2025 the signing of an agreement for the sale of approximately 29.6 million Sanofi shares to Sanofi at a price of €101.5 per share, for a total consideration of €3 billion. Following the transaction and after cancellation of the repurchased shares, L'Oréal will hold 7.2% of Sanofi's share capital and 13.1% of the voting rights(1).
The transaction, which will be carried out through an off-market block trade, is not subject to any condition precedent and should be finalized in the coming days.
(1) Based on a total number of shares of 1,263,122,721 and a total actual number of voting rights of 1,413,130,110 as of 31 December 2024, as published by Sanofi, it being specified that the percentage of theoretical voting rights held by L’Oréal after cancellation will be 13.0% based on the total number of 1,422,661,191 theoretical voting rights as of 31 December 2024, as published by Sanofi, in each case, restated for the number of shares repurchased and cancelled following or as a result of this transaction. Before cancellation of the repurchased shares, L’Oréal’s stake in Sanofi will amount to 7.0% of the share capital and 12.7% of the total number of theoretical voting rights.
